Download MendeleyNovel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.
Dragovich, P.S., Blazel, J.K., Ellis, D.A., Han, Q., Kamran, R., Kissinger, C.R., LeBrun, L.A., Li, L.S., Murphy, D.E., Noble, M., Patel, R.A., Ruebsam, F., Sergeeva, M.V., Shah, A.M., Showalter, R.E., Tran, C.V., Tsan, M., Webber, S.E., Kirkovsky, L., Zhou, Y.(2008) Bioorg Med Chem Lett 18: 5635-5639
- PubMed: 18796353
- DOI: https://doi.org/10.1016/j.bmcl.2008.08.094
- Primary Citation of Related Structures:
3E51 - PubMed Abstract:
The synthesis of 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones bearing 6-amino substituents as potent inhibitors of the HCV RNA-dependent RNA polymerase (NS5B) is described. Several of these agents also display potent antiviral activity in cell culture experiments (EC(50)<0.10 microM). In vitro DMPK data (microsome t(1/2), Caco-2 P(app)) for many of the compounds are also disclosed, and a crystal structure of a representative inhibitor complexed with the NS5B protein is discussed.
Organizational Affiliation:
Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA. pdragovich@anadyspharma.com
